These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 18191202)

  • 1. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
    Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
    Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
    Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
    Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
    Coutinho R; Costa D; Carrió A; Muñoz C; Vidal A; Belkaid M; Campo E; Nomdedeu B
    Ann Hematol; 2010 Oct; 89(10):1069-70. PubMed ID: 20232065
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C
    Leuk Res; 2006 Apr; 30(4):385-8. PubMed ID: 16219350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
    Komrokji RS; List AF
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
    Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C
    Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 18. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
    Ortega J; List A
    Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.